Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amanta HealthcareNSE:AMANTA -2.00%26 EBITDA Margin % is 21.58% as of Mar. 2026, which is 0% above its 10-year median of 21.52. GuruFocus rates NSE:AMANTA with a GF Score™ of 26/100. The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Amanta Healthcare ranks better than 68.16% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Amanta Healthcare's EBITDA for the
three
months ended in Mar. 2026 was ₹166 Mil. Amanta Healthcare's Revenue for the
three
months ended in Mar. 2026 was ₹770 Mil. Therefore, Amanta Healthcare's EBITDA margin for the quarter that ended in Mar. 2026 was 21.58%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Amanta Healthcare EBITDA Margin % Related Terms
Amanta Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Amanta Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:AMANTA vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amanta Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amanta Healthcare EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amanta Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Amanta Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amanta Healthcare (NSE:AMANTA) has a EBITDA Margin % of 21.58% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amanta Healthcare and its competitors. This is near median its historical median of 21.52. Over the past decade, Amanta Healthcare's EBITDA Margin % has ranged from 20.12 to 54.52. According to the industry distribution chart, Amanta Healthcare ranks #306 out of 961 companies in the Drug Manufacturers industry, placing it in the top 31.8%.
Is Amanta Healthcare's EBITDA Margin % too high?
Amanta Healthcare's current EBITDA Margin % of 21.58% is near median its 10-year median of 21.52. Over the past 10 years, this metric has ranged from a low of 20.12 to a high of 54.52. The Drug Manufacturers industry median EBITDA Margin % is 12.49. Amanta Healthcare's value of 21.58% is 72.8% above this industry median. Based on the distribution chart, Amanta Healthcare ranks #306 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amanta Healthcare has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Amanta Healthcare's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Amanta Healthcare ranks #306 out of 961 companies for EBITDA Margin %. This puts Amanta Healthcare in the upper half of its industry. The industry median EBITDA Margin % is 12.49. Amanta Healthcare's value of 21.58% is 72.8% above this benchmark. Historically, Amanta Healthcare's own EBITDA Margin % has ranged from 20.12 to 54.52 over the past decade. While the company's 10-year median is 21.52 vs. the industry median of 12.49, Amanta Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amanta Healthcare's current EBITDA Margin % of 21.58% is 72.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Amanta Healthcare and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amanta Healthcare's current EBITDA Margin % is 21.58%, which is near median its own 10-year median of 21.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amanta Healthcare stock overvalued right now?
Amanta Healthcare (NSE:AMANTA) has a current EBITDA Margin % of 21.58%. The current EBITDA Margin % is 21.58%, which is near median its 10-year median of 21.52 and 72.8% above the Drug Manufacturers industry median of 12.49. Amanta Healthcare's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Amanta Healthcare (NSE:AMANTA), the current EBITDA Margin % is 21.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amanta Healthcare Ltd is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal and Injection Strech Blow Moulding technology. It manufactures large volume parenterals and small volume parenterals in six therapeutic segments. It also manufactures medical devices. The company manufactures fluid therapy, formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc. in medical device segment. It offers wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume till 1000 ml.
26GF Score
Get the complete analysis for NSE:AMANTA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AMANTA has been successfully added to your 
